2026 ACC/AHA Dyslipidemia Guideline Summary
This is a condensed summary of the 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia for Atherosclerotic Cardiovascular Disease Risk Reduction (Blumenthal et al., Circulation 2026;153:e00–e00). This replaces the 2018 Guideline on the Management of Blood Cholesterol. Recommendations are listed by Class of Recommendation (COR) and Level of Evidence (LOE).
🔹 Bottom Line: Key Changes from 2018 Guideline
- PREVENT-ASCVD replaces PCE (Pooled Cohort Equations): New risk equations estimate both 10-year and 30-year ASCVD (atherosclerotic cardiovascular disease) risk, include kidney function (eGFR) and HbA1c, and remove race as a variable
- 30-year risk added: For adults with low 10-year risk but high 30-year risk (≥10%), initiating LLT (lipid-lowering therapy) is reasonable to reduce cumulative atherogenic exposure
- LDL-C + non-HDL-C dual targets: All treatment thresholds now specify both LDL-C (low-density lipoprotein cholesterol) and non-HDL-C goals
- ApoB (apolipoprotein B) endorsed as optional target: Can be used for residual risk assessment, especially in hypertriglyceridemia
- Ezetimibe before PCSK9i (PCSK9 inhibitor): Ezetimibe no longer requires failing before adding PCSK9 mAb (monoclonal antibody) — can be added simultaneously or sequentially based on degree of LDL-C lowering needed
- Bempedoic acid elevated: Now has ASCVD outcomes data (CLEAR Outcomes) — COR (Class of Recommendation) 2a for secondary prevention, primary prevention in statin-intolerant
- Inclisiran included: Approved for LDL-C lowering; CVOT (cardiovascular outcomes trial) data pending — considered second-line PCSK9 inhibitor (COR 2a)
- CAC (coronary artery calcium)-guided treatment expanded: Detailed tiered recommendations by CAC score (1–99, 100–299, 300–999, ≥1000) with specific LDL-C goals
- HeFH (heterozygous familial hypercholesterolemia) management refined: FH-specific risk scores now available; standard PREVENT-ASCVD should NOT be used for FH
- Lp(a) (lipoprotein(a)) recommendations formalized: Elevated Lp(a) ≥50 mg/dL (≥125 nmol/L) warrants early aggressive risk factor management
🧠 Bottom Line for Neurologists
- Ischemic stroke & TIA are qualifying ASCVD events — all post-stroke patients merit high-intensity statin therapy
- Most stroke patients qualify as “very high risk” → LDL-C target <55 mg/dL: Ischemic stroke counts as a major ASCVD event. “Very high risk” = ≥2 major events OR 1 major event + ≥2 high-risk conditions (HTN, diabetes, age >65, CAD, HF, current smoking, LDL-C >100 on max therapy). Since most stroke patients have at least 2 of these comorbidities, the majority will meet very high risk criteria and need LDL-C <55, non-HDL-C <85
- ICAD (intracranial atherosclerotic disease): Recurrent stroke despite medical therapy → very high risk → LDL-C target <55 mg/dL. TST trial showed LDL-C <70 reduced recurrent stroke by 22% vs a 90–110 mg/dL target
- Large artery atherosclerosis stroke: Aggressive lipid management with high-intensity statin ± ezetimibe ± PCSK9 mAb. FOURIER showed ~21% stroke reduction (HR 0.79); ODYSSEY showed 27% stroke reduction
- Carotid stenosis post-CEA/CAS: Secondary prevention targets apply — LDL-C <70 (or <55 if very high risk)
- Drug interactions: Avoid simvastatin/lovastatin with CYP3A4-inhibiting drugs. Enzyme-inducing AEDs (carbamazepine, phenytoin) reduce statin efficacy → use rosuvastatin or pravastatin. Cyclosporine (MG, transplant) → lowest statin dose
- Anti-HMGCR necrotizing myopathy: Rare but important — persistent proximal weakness + elevated CK after statin discontinuation → check anti-HMGCR antibodies → requires immunosuppression
1. Screening & Lipid Measurement
Who to Screen
- Universal lipid screening in children and adolescents at age 9–11 years and again at 17–21 years (COR 1, LOE B-NR)
- In adults ≥20 years, measure fasting or nonfasting lipid panel as part of global CVD risk assessment (COR 1, LOE B-NR)
- Earlier screening at ages 2+ if family history of premature CVD or FH
What to Measure
| Marker | Key Points | When Preferred |
|---|---|---|
| LDL-C | Primary target for LLT. Fasting vs nonfasting differ minimally (~8 mg/dL). If TG >400, direct LDL-C or use Martin-Hopkins equation | All patients |
| Non-HDL-C | = TC − HDL-C. Captures all atherogenic lipoproteins (LDL + VLDL + IDL + Lp(a)). Does NOT require fasting | When TG elevated; secondary target alongside LDL-C |
| ApoB | Direct count of atherogenic particles. Better predictor when LDL-C discordant with non-HDL-C. Goal: <55–90 mg/dL based on risk | Hypertriglyceridemia, metabolic syndrome, diabetes, residual risk assessment |
| Lp(a) | Genetically determined, mostly stable over life. ≥50 mg/dL (≥125 nmol/L) = elevated. Screen once. Assays NOT standardized — report in nmol/L preferred | Once in all adults; family history of premature CVD; recurrent events despite optimal LLT |
| Triglycerides | Fasting TG ≥150 mg/dL = persistent hypertriglyceridemia. ≥500 mg/dL = pancreatitis risk. Non-fasting TG ≥175 mg/dL triggers fasting confirmation | All patients; fasting if elevated nonfasting |
Monitoring Lipids on Therapy
- Repeat lipid panel 4–12 weeks after initiating or adjusting LLT (COR 1, LOE A)
- Then repeat every 3–12 months as needed to assess adherence and LDL-C attainment
- Routine hepatic transaminase or CK monitoring is NOT recommended in asymptomatic patients on statins (COR 3: No Benefit)
2. Risk Assessment
PREVENT-ASCVD Equations (Replaces PCE)
- Use for adults 30–79 years without established ASCVD (COR 1, LOE B-NR)
- Estimates 10-year and 30-year risk of ASCVD (MI, stroke, fatal CHD)
- New variables: eGFR, HbA1c (or diabetes status), zip code–level Social Deprivation Index
- Race removed — focuses on modifiable risk factors and social determinants
- Risk categories: <3% borderline → 3–<5% borderline → 5–<10% intermediate → ≥10% high
- 30-year risk ≥10% in low 10-year risk patients may justify LLT initiation
- Calculator: prevent.heart.org
PREVENT-ASCVD Risk Calculator
Estimates 10-year and 30-year ASCVD risk — replaces PCE. For adults 30–79 years without established ASCVD.
Female
Male
10-Year ASCVD Risk
30-Year ASCVD Risk
Simplified estimate using published PREVENT coefficients (Khan SS et al., Circulation 2024). For official calculator with SDI zip code adjustment, use prevent.heart.org
Risk Enhancers
- Family history of premature ASCVD (men <55 y, women <65 y)
- Persistently elevated LDL-C ≥160 mg/dL
- Metabolic syndrome
- Chronic kidney disease (eGFR 15–59)
- Chronic inflammatory conditions (RA, SLE, psoriasis, HIV)
- South Asian ancestry
- Premature menopause (<40 y) or preeclampsia history
- Elevated Lp(a) ≥50 mg/dL (≥125 nmol/L)
- Elevated apoB ≥130 mg/dL
- Elevated hsCRP ≥2 mg/L
- Ankle-brachial index <0.9
Coronary Artery Calcium (CAC) Scoring
- Use for shared decision-making in borderline or intermediate risk (3–<10%) when treatment decision is uncertain (COR 2a, LOE B-NR)
- CAC = 0: Withhold statins unless FH, diabetes, or heavy smoking (COR 2b)
- CAC 1–99: Moderate-intensity statin reasonable
- CAC ≥100: Statin therapy with LDL-C–lowering is recommended (COR 1)
- CAC ≥300 or ≥75th percentile: Treat like intermediate-high risk; LDL-C goal <70 mg/dL (COR 1, LOE B-R)
- CAC ≥1000: Treat like established ASCVD; LDL-C goal <55 mg/dL (COR 1, LOE B-NR)
- CAC is NOT indicated in patients with FH — they should be treated regardless
3. Lifestyle Management
- Diet: Emphasize vegetables, fruits, legumes, nuts, whole grains, fish (Mediterranean/DASH pattern). Limit saturated fat <5–6% of calories. Avoid trans fats. (COR 1, LOE A)
- Physical activity: ≥150 min/week moderate-intensity or ≥75 min/week vigorous aerobic exercise (COR 1, LOE A)
- Weight management: 5–10% weight loss lowers TG by 20–30% and modestly reduces LDL-C
- Alcohol: Reduce or eliminate — particularly for hypertriglyceridemia
- Supplements: Fish oil, plant stanols/sterols, and psyllium fiber may modestly lower lipids but do NOT substitute for pharmacotherapy in high-risk patients
- Referral to dietitian: Reasonable for refractory hypertriglyceridemia or complex lipid phenotypes (COR 2a)
4. Pharmacological Therapy
Statin Intensity
| Intensity | Expected LDL-C Reduction | Agents |
|---|---|---|
| High | ≥50% | Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg |
| Moderate | 30–49% | Atorvastatin 10–20 mg, Rosuvastatin 5–10 mg, Simvastatin 20–40 mg, Pravastatin 40–80 mg, Lovastatin 40–80 mg, Fluvastatin XL 80 mg, Pitavastatin 1–4 mg |
| Low | <30% | Simvastatin 10 mg, Pravastatin 10–20 mg, Lovastatin 20 mg, Fluvastatin 20–40 mg |
Non-Statin LDL-C–Lowering Agents
| Agent | Mechanism | LDL-C Reduction | Key Points |
|---|---|---|---|
| Ezetimibe | Cholesterol absorption inhibitor | ~18–25% | Well tolerated, generic, first-line add-on. IMPROVE-IT showed MACE reduction in ACS (NNT 50 over 6 y) |
| PCSK9 mAb (evolocumab, alirocumab) | PCSK9 inhibition → ↑ LDL receptor recycling | ~50–60% | FOURIER & ODYSSEY: 1.5% ARR in MACE over ~2.5 y. Subcutaneous injection q2w or monthly. Cost-effective at $5,850/y |
| Bempedoic acid | ACL inhibitor (upstream of HMG-CoA reductase) | ~18–20% | CLEAR Outcomes: 13% RRR in MACE. Does NOT cause myalgia (prodrug activated in liver, not muscle). Elevates BUN, creatinine, uric acid |
| Inclisiran | siRNA targeting PCSK9 mRNA | ~50% | Subcutaneous injection every 6 months. CVOT pending (ORION 4, VICTORION-2). Second-line PCSK9i. Administered by clinician |
| Bile acid sequestrants | Bile acid binding → ↑ hepatic LDL-R expression | ~15–30% | Contraindicated if TG >500. GI side effects limit use. Colesevelam safest in pregnancy. Drug interactions |
Triglyceride-Lowering Agents
| Agent | Mechanism | TG Reduction | Key Points |
|---|---|---|---|
| Icosapent ethyl (IPE) | Purified EPA | ~19% | REDUCE-IT: 25% RRR in MACE. For ASCVD or diabetes with TG 150–499 on statin. Increased bleeding and AF. Mineral oil placebo concern |
| Fibrates (fenofibrate) | PPARα agonist | 30–50% | Lower TG; do NOT reduce ASCVD events as add-on to statin. For pancreatitis prevention with TG ≥500. Avoid gemfibrozil with statins (↑ myopathy). Fenofibrate preferred |
| Omega-3 fatty acids (prescription) | ↓ VLDL synthesis | 20–50% | DHA-containing formulations can raise LDL-C. EPA-only (IPE) preferred for ASCVD reduction |
| Olezarsen | ApoC-III antisense oligonucleotide | ~44% | FDA-approved for FCS only. Phase 3 showed significant TG reduction |
| Niacin | ↓ VLDL synthesis | 20–30% | NOT recommended — poor tolerability, no ASCVD benefit when added to statin (AIM-HIGH, HPS2-THRIVE) |
5. Primary Prevention
Adults 30–79 Years, LDL-C 70–189 mg/dL
- First step for ALL: Lifestyle optimization at every risk level (COR 1, LOE A)
- LDL-C <70 and non-HDL-C <100: No clear net benefit to initiate LLT
| 10-Year Risk | Recommendation | Goal |
|---|---|---|
| <3% (Borderline) | Healthy behavior counseling. Consider LLT if 30-year risk ≥10% or multiple risk enhancers | LDL-C <100 mg/dL, non-HDL-C <130 |
| 3–<5% (Borderline) | Benefit-risk discussion. Moderate-intensity statin reasonable if risk enhancers present | LDL-C <100, non-HDL-C <130 |
| 5–<10% (Intermediate) | Moderate-intensity statin for ≥30% LDL-C reduction (COR 1, LOE A). High-intensity reasonable if risk enhancers | LDL-C <100 → <70 if high-intensity; non-HDL-C <100 |
| ≥10% (High) | High-intensity statin for ≥50% LDL-C reduction (COR 1, LOE A) | LDL-C <70, non-HDL-C <100 |
LDL-C ≥160 mg/dL
- Regardless of calculated risk, lifestyle counseling is essential
- Benefit from earlier LLT initiation based on both 10-year and 30-year risk
- Screen for secondary causes: hypothyroidism, nephrotic syndrome, obstructive liver disease, drugs (thiazides, glucocorticoids, atypical antipsychotics, cyclosporine)
6. Secondary ASCVD Prevention
Clinical ASCVD includes: history of MI, ACS, stable angina, coronary revascularization, stroke, TIA, PAD (symptomatic), or aortic aneurysm of atherosclerotic origin.
“Very High Risk” Definition
- ≥2 major ASCVD events (ACS within 12 mo, MI, ischemic stroke, symptomatic PAD), OR
- 1 major ASCVD event + ≥2 high-risk conditions (age >65, CABG/PCI, current smoker, diabetes, HF, HTN, LDL-C >100 despite max tolerated statin + ezetimibe)
Treatment Recommendations
| Patient Group | Statin | Add-on | LDL-C Goal | Non-HDL-C Goal |
|---|---|---|---|---|
| ASCVD — Not very high risk | High-intensity (COR 1, LOE A) | Ezetimibe, PCSK9 mAb, or bempedoic acid if not at goal (COR 2a) | <70 mg/dL | <100 mg/dL |
| ASCVD — Very high risk | High-intensity (COR 1, LOE A) | Ezetimibe AND/OR PCSK9 mAb (COR 1, LOE A); bempedoic acid (COR 2a) | <55 mg/dL | <85 mg/dL |
| Statin intolerance + ASCVD | Reduced-dose or alternate statin | Bempedoic acid, ezetimibe, PCSK9 mAb, inclisiran | Same as above | Same as above |
- Optional apoB goal <55 mg/dL for very high risk; <70 mg/dL for high risk
- Evidence indicates long-term safety and efficacy of LDL-C to a median of 30 mg/dL over 8 years — no signal for de-escalation
7. Severe Hypercholesterolemia (LDL-C ≥190 mg/dL)
Familial Hypercholesterolemia (FH)
- Prevalence of HeFH: ~1:250. Significantly underdiagnosed
- 2- to 4-fold lifetime ASCVD risk vs general population; adults <35 y up to 17-fold
- Do NOT use PREVENT-ASCVD or PCE for FH patients — they underestimate risk
- FH-specific risk scores available: Montreal-FH-SCORE, SAFEHEART, FH-Risk Score
- CAC = 0 does NOT justify deferring statins in FH
- Genetic testing for LDLR, APOB, PCSK9 recommended in possible/probable/definite FH (COR 1, LOE B-NR)
- Cascade screening of first-degree relatives (COR 1)
Dutch Lipid Clinic Network (DLCN) Score — FH Diagnosis
Clinical diagnostic criteria for Familial Hypercholesterolemia. Select all that apply:
Family History
Clinical History
Physical Examination
LDL-C Level (untreated, highest score only)
Genetic Testing
DLCN Score
Treatment by Scenario
| Scenario | Treatment | LDL-C Goal |
|---|---|---|
| LDL-C ≥190, no FH, no ASCVD, no risk factors | Max tolerated statin + ezetimibe/PCSK9 mAb/bempedoic acid | <100 mg/dL |
| LDL-C ≥190, HeFH or risk factors, no ASCVD | Max statin + ezetimibe + PCSK9 mAb and/or bempedoic acid | <70 mg/dL |
| LDL-C ≥190 + clinical ASCVD | Max statin + ezetimibe + PCSK9 mAb + bempedoic acid | <55 mg/dL |
| HoFH | All above + evinacumab (COR 2b) ± lomitapide (COR 2b) ± lipoprotein apheresis | <100 mg/dL |
Lipoprotein Apheresis Indications
- HoFH homozygotes with LDL-C >500 mg/dL
- HeFH heterozygotes with LDL-C ≥300 mg/dL
- HeFH with documented CAD + LDL-C ≥70 mg/dL
- HeFH with Lp(a) ≥60 mg/dL + documented CAD/PAD
8. Diabetes Without ASCVD
| Age Group | Recommendation | Goal |
|---|---|---|
| 40–75 y | Moderate-intensity statin (COR 1, LOE A). If multiple risk factors → high-intensity for ≥50% reduction (COR 2a) | LDL-C <100, non-HDL-C <130 → <70 and <100 if high risk |
| >75 y | Benefit-risk discussion; moderate-intensity statin reasonable (COR 2b) | Same goals if treated |
| 20–39 y | Moderate-intensity statin reasonable if long-standing diabetes (≥10 y T2DM or ≥20 y T1DM) with risk enhancers (COR 2b) | LDL-C <100 |
Diabetes-Specific Risk Enhancers
- Long duration (≥10 y T2DM or ≥20 y T1DM)
- Albuminuria ≥30 μg albumin/mg creatinine
- eGFR <60 mL/min/1.73 m²
- Retinopathy, neuropathy
- ABI <0.9
- If diabetes + ASCVD + TG 150–499 + LDL-C <100 on max statin: icosapent ethyl may be considered (COR 2b)
- Statin therapy slightly increases new-onset diabetes risk (HbA1c increases ~0.06–0.08%) — NOT a reason to discontinue (COR 1, LOE A)
9. Subclinical Atherosclerosis (CAC-Guided Therapy)
| CAC Score | Treatment | LDL-C Goal |
|---|---|---|
| 0 | May defer LLT (unless FH, diabetes, heavy smoking) | — |
| 1–99 AU (<75th %ile) | Moderate-intensity statin (COR 2a) | <100 mg/dL |
| 100–299 AU or ≥75th %ile | Statin + LDL-C–lowering; ≥50% reduction (COR 1) | <70 mg/dL |
| 300–999 AU | Intensify therapy; add ezetimibe, PCSK9 mAb, or bempedoic acid (COR 2a) | <55 mg/dL (optional) |
| ≥1000 AU | Treat like established ASCVD (COR 1) | <55 mg/dL |
| Incidental CAC on nongated CT | Moderate-to-severe: initiate high-intensity statin (COR 2a). Mild: ≥30% LDL-C reduction (COR 2a) | <70 mg/dL |
10. Hypertriglyceridemia
Classification
- Normal: TG <150 mg/dL (fasting) or <175 mg/dL (nonfasting)
- Moderate: 150–499 mg/dL — ASCVD risk
- Severe: ≥500 mg/dL — pancreatitis risk
- Very severe: ≥1000 mg/dL — consider FCS screening
Secondary Causes to Rule Out
- Diseases: Uncontrolled diabetes, hypothyroidism, nephrotic syndrome, CKD, liver disease, Cushing syndrome, SLE
- Drugs: Glucocorticoids, estrogens, atypical antipsychotics (olanzapine, clozapine), thiazides, beta-blockers, cyclosporine, tacrolimus, isotretinoin, protease inhibitors, tamoxifen, bile acid sequestrants
- Diet/Lifestyle: Alcohol, high-sugar/high-glycemic diet, sedentary lifestyle, obesity
Treatment Algorithm
- Step 1: Address secondary causes, optimize diet (reduce alcohol, sugars, refined carbs), exercise, weight loss 5–10%
- Step 2: Maximize statin and LDL-C–lowering therapy (statins lower TG 20–40%)
- Step 3 (ASCVD + TG 150–499): Consider IPE 4 g/day if LDL-C <100 and non-HDL-C <130 on max statin (COR 2b based on REDUCE-IT)
- Step 3 (No ASCVD, TG 150–499): Estimate 10-year risk with PREVENT-ASCVD → optimize statin/LDL-C targets → consider fibrate or omega-3 for persistent TG ≥500
- TG ≥500: Fibrate or prescription omega-3 to reduce pancreatitis risk (COR 2a). For FCS: olezarsen (COR 1)
- TG ≥1000 (FCS): Very-low-fat diet (<10–15% of calories from fat) + fibrate/omega-3 + olezarsen + lipid specialist referral
- When hypertriglyceridemia present and LDL-C/non-HDL-C discordant: apoB preferred over LDL-C for clinical decision-making (COR 2a)
11. Elevated Lp(a)
- Elevated Lp(a) ≥50 mg/dL (≥125 nmol/L) affects ~20% of the population
- Risk is multiplicative with other risk factors (not merely additive)
- An Lp(a) of ~80–100 mg/dL (~200–250 nmol/L) doubles ASCVD risk; 180 mg/dL (~430 nmol/L) increases risk ~4-fold (equivalent to HeFH risk)
- Statins do NOT lower Lp(a) — may modestly increase it. This is NOT a reason to discontinue
- PCSK9 mAb + lipoprotein apheresis lower Lp(a) as well as LDL-C
- Specific Lp(a)-lowering therapies (mRNA therapies, oral small-molecule inhibitors) are in clinical trials
Management Recommendations
- In ALL individuals with elevated Lp(a): optimal early control of modifiable CV risk factors (COR 1, LOE B-NR)
- If ASCVD + elevated Lp(a) + not at LDL-C/non-HDL-C goal on max statin: add PCSK9 mAb (COR 1, LOE B-R) — addresses both LDL-C and Lp(a)
- Post hoc FOURIER and ODYSSEY analyses suggest additional benefit in patients with Lp(a) ≥50 mg/dL
- Lipoprotein apheresis is FDA-approved for Lp(a) ≥60 mg/dL (or 130 nmol/L) with FH and CAD/PAD
12. Statin-Attributed Muscle Symptoms (SAMS)
Key Principles
- Most commonly reported reason for statin non-adherence (~10% in real-world data)
- In RCTs, muscle symptom rates are similar between statin and placebo — “drucebo effect” is common
- True statin-related myalgia: bilateral, symmetrical, proximal, onset weeks after initiation, resolves with discontinuation, recurs on rechallenge
- Rhabdomyolysis is very rare (~1:100,000)
- Statin-induced immune-mediated necrotizing myopathy (anti-HMGCR antibodies) is very rare; requires statin cessation + immunotherapy
- CoQ10 supplementation is NOT recommended (COR 3: No Benefit, LOE B-R)
- Routine CK monitoring is NOT useful in asymptomatic patients (COR 3: No Benefit)
Risk Factors for SAMS
- Age ≥65, low body mass, female sex
- Hypothyroidism, CKD, chronic liver disease, diabetes
- Alcohol consumption, vigorous exercise
- High-dose statin therapy
- Drug-drug interactions (especially CYP3A4 inhibitors with lovastatin/simvastatin)
- Diseases associated with myalgia (fibromyalgia, polymyalgia rheumatica, primary myopathies)
- Gene variants affecting statin metabolism (e.g., SLC01B1)
Management Algorithm
- Step 1: Evaluate for secondary causes (DDI, hypothyroidism, exercise). If severe weakness or CK ≥10× ULN: withhold statin, pursue neurologic evaluation
- Step 2: Benefit-risk discussion — reinforce ASCVD risk of discontinuation
- Step 3: Try alternate statin, lower dose, or every-other-day dosing (long-acting statin: rosuvastatin or atorvastatin)
- Step 4: If truly intolerant to ≥2 statins at lowest dose:
- Bempedoic acid (no muscle side effects — hepatic prodrug) ± ezetimibe (COR 1)
- PCSK9 mAb (COR 1 for ASCVD; fewer musculoskeletal side effects than statins)
- Inclisiran (COR 2a — for those unable to tolerate/obtain PCSK9 mAb)
- If borderline risk and uncertain about nonstatin therapy: CAC scoring can aid decision (CAC = 0 → may reasonably defer)
13. Drug Interactions
Statin Metabolism & Key Interactions
| Statin | Primary CYP Pathway | DDI Risk |
|---|---|---|
| Lovastatin, Simvastatin | CYP3A4 | Highest — avoid with strong CYP3A4 inhibitors |
| Atorvastatin | CYP3A4 (lesser extent) | Moderate — dose adjustments with CYP3A4 inhibitors |
| Fluvastatin | CYP2C9 | Low |
| Pitavastatin | CYP2C9 (minimal) | Low |
| Rosuvastatin | CYP2C9 (minimal) | Low |
| Pravastatin | Not CYP-metabolized | Lowest |
Cardiovascular Drug Interactions (Table 27)
| Interacting Drug | Affected Statin | Recommendation |
|---|---|---|
| Amiodarone | Lovastatin, Simvastatin | Limit lovastatin to 40 mg, simvastatin to 20 mg daily |
| Diltiazem | Lovastatin, Simvastatin | Limit lovastatin to 20 mg, simvastatin to 10 mg daily |
| Verapamil | Lovastatin, Simvastatin | Limit lovastatin to 20 mg, simvastatin to 10 mg daily |
| Dronedarone | Lovastatin, Simvastatin | Limit both to 10 mg daily |
| Gemfibrozil | ALL statins | Avoid combination with all statins (↑ rhabdomyolysis risk). Use fenofibrate instead |
| Colchicine | Atorvastatin, Fluvastatin, others | Monitor for muscle toxicity |
| Ticagrelor | Lovastatin, Simvastatin | Limit to 40 mg daily; atorvastatin acceptable without dose limits |
| Ranolazine | Lovastatin, Simvastatin | Limit to 20 mg daily (use non-CYP3A4 statin if possible) |
| Bempedoic acid | Pravastatin, Simvastatin | Limit pravastatin to 40 mg, simvastatin to 20 mg daily |
| Lomitapide | Lovastatin, Simvastatin | Reduce lovastatin by 50%, limit simvastatin by 50% and ≤20 mg daily |
Antiretroviral Interactions
- Protease inhibitors: Simvastatin and lovastatin are contraindicated. Limit atorvastatin/rosuvastatin doses. Pitavastatin and pravastatin are safe
- NNRTIs (efavirenz, etravirine): Adjust statin dose; do not exceed max recommended dose
- INSTIs (bictegravir, dolutegravir, raltegravir): Generally no adjustment needed
- Elvitegravir/cobicistat: CYP3A4 inhibitor — avoid simvastatin; limit atorvastatin to 20 mg
- Pitavastatin was the statin studied in REPRIEVE (35% MACE reduction in HIV) — preferred due to minimal CYP3A4 metabolism
14. Special Populations
Children & Adolescents
- Lifestyle management first (COR 1, LOE B-R)
- If LDL-C persistently ≥160 with FH and 3–6 months lifestyle fails: initiate statin at age ≥8 (COR 1, LOE B-R)
- Genetic testing for FH in children with clinical presentation (COR 2a)
- HoFH: aggressive LLT from diagnosis (often in infancy), lipid specialist + pediatric cardiology
Young Adults (18–39 y)
- Prioritize lifestyle and weight optimization to reduce cumulative atherogenic lipid exposure (COR 1, LOE B-NR)
- If high atherogenic lipid burden + risk enhancers: LLT may be reasonable (clinical judgment)
Older Adults (>75 y)
- Consider patient priorities, functional status, multimorbidity, frailty, polypharmacy, life expectancy (COR 1, LOE C-EO)
- Estimated life expectancy ≥2.5 y: may be reasonable to initiate moderate-intensity statin (COR 2b, LOE B-NR)
- Life expectancy <1 y: reasonable to discontinue LLT for QOL (COR 2b, LOE B-R)
- CAC = 0 in absence of diabetes/active smoking: LLT benefits unlikely to outweigh risks
- If already on statin for secondary prevention: generally continue unless life expectancy very limited
Pregnancy & Lactation
- Stop statins 1–2 months before planned pregnancy or as soon as pregnancy is discovered (COR 1, LOE C-LD)
- Bile acid sequestrants are safest during pregnancy (no systemic absorption)
- HoFH: lipoprotein apheresis is reasonable during pregnancy (COR 2a)
- Severe gestational hypertriglyceridemia (TG ≥500): fibrates (after first trimester) or omega-3 are reasonable to prevent pancreatitis (COR 2a)
- Statins may be considered in very high-risk FH/ASCVD patients after individualized benefit-risk discussion (COR 2b)
CKD (Stage 3 or Higher)
- CKD ≥ stage 3 without ASCVD, LDL-C 70–189: moderate-intensity statin + ezetimibe recommended (COR 1, LOE B-R)
- CKD + clinical ASCVD: high-intensity statin ± ezetimibe ± PCSK9 mAb; LDL-C <55 (COR 1, LOE B-R)
- Dialysis: initiation of statin NOT beneficial (4D, AURORA, SHARP subgroup). Continuation of pre-existing statin may be reasonable (COR 2b)
- Rosuvastatin concentrations may increase in severe CKD (<30 mL/min) — limit to ≤10 mg. Atorvastatin preferred for renal clearance independence
HIV
- Adults 40–75 y on stable ART: statin therapy recommended (COR 1, LOE B-R)
- REPRIEVE trial: pitavastatin 4 mg daily → 35% RRR in first MACE (HR 0.65, p=0.002)
- Pitavastatin or pravastatin preferred (minimal CYP3A4 metabolism, fewer DDI with ART)
Heart Failure
- HFrEF without ASCVD indication: LLT is NOT recommended (COR 3: No Benefit, LOE A) — CORONA and GISSI-HF showed no benefit
- HFrEF with ischemic etiology + life expectancy 3–5 y and not on statin: may be reasonable (COR 2b)
- If already on statin for ASCVD and develops HF: continue therapy
Chronic Inflammatory Diseases
- RA, SLE, psoriatic arthritis, IBD, spondyloarthritis → higher ASCVD risk
- Standard risk calculators underestimate risk in CID
- LLT can be used safely; monitor lipids as anti-inflammatory therapy (glucocorticoids, hydroxychloroquine, tocilizumab) can modify lipid profiles
Cancer Survivors
- ≥2-year cancer survivors with life expectancy ≥2 y: treat per standard guidelines (COR 1, LOE B-NR)
- Active cancer on statin: continue unless DDI concern or life expectancy <1 y (COR 1, LOE B-NR)
- Statins may prevent anthracycline-induced cardiotoxicity (COR 2b, LOE B-R)
15. Medication Safety
| Medication | Common Side Effects | Contraindications | Key Safety Points |
|---|---|---|---|
| Statins | Myalgia (normal CK), dose-related | Decompensated cirrhosis; severe neuromuscular diseases (NMDs); pregnancy (relative) | Rhabdomyolysis very rare (~1:100K). Anti-HMGCR necrotizing myopathy very rare. Transaminase elevation >3× ULN in ~3%. Cognitive complaints reversible on discontinuation. Slight ↑ new-onset diabetes (0.06–0.08% HbA1c) |
| Ezetimibe | Typically well tolerated | Hypersensitivity; moderate-severe hepatic impairment | Monitor hepatic transaminases when adding to statin |
| PCSK9 mAb | Injection site reactions | Hypersensitivity | Rare angioedema. No latex in alirocumab (but present in some evolocumab devices) |
| Bempedoic acid | Elevated BUN, creatinine, uric acid | Hypersensitivity | Does NOT cause myalgia (prodrug activated only in liver). Monitor renal function and uric acid |
| Inclisiran | Injection site reactions | Hypersensitivity | Administered by clinician q6 months. CVOT pending |
| Fibrates | Myalgia, elevated transaminases | Severe renal/hepatic disease; gallbladder disease; lactation | Gemfibrozil + statin → ↑ rhabdomyolysis. Use fenofibrate. Reversibly elevates creatinine |
| Omega-3 (IPE) | Eructation, dysgeusia | Hypersensitivity to fish/shellfish | New-onset AF/flutter; increased bleeding events. DHA-containing products can raise LDL-C |
16. Neurological Considerations
Stroke Prevention
- Ischemic stroke is included as a qualifying ASCVD event for secondary prevention
- Post-stroke/TIA patients qualify as “very high risk” if ≥2 major events or 1 event + ≥2 high-risk conditions
- High-intensity statin is first-line for secondary stroke prevention; target LDL-C <70 mg/dL (not very high risk) or <55 mg/dL (very high risk)
- PCSK9 mAb can be added if not at goal — FOURIER showed ~21% reduction in stroke (HR 0.79), ODYSSEY showed 27% reduction in stroke with alirocumab
Statin Safety in Neurological Patients
- Cognitive effects: Postmarketing reports of memory loss/confusion are generally nonserious, reversible upon discontinuation, and NOT observed in prospective clinical trials. NOT a reason to avoid statins
- Hemorrhagic stroke: SPARCL showed modest increased ICH risk with high-dose atorvastatin (HR 1.66). However, overall stroke recurrence was reduced. Guideline does not restrict statin use after ICH
- Neuromuscular diseases: Statins are relatively contraindicated in severe NMDs. However, most myopathy patients can tolerate statins at low doses
- Anti-HMGCR necrotizing myopathy: Very rare immune-mediated myopathy requiring statin cessation, immunosuppressive therapy. Check anti-HMGCR antibodies if persistent weakness/CK elevation after statin discontinuation
- Peripheral neuropathy: Rare case reports; not confirmed in large studies. Not a listed side effect
Drug Interactions Relevant to Neurologists
- Antiepileptics: Carbamazepine, phenytoin, phenobarbital (CYP3A4 inducers) may reduce statin efficacy — may need higher statin doses or use non-CYP3A4 statin
- Cyclosporine (used in myasthenia gravis, transplant): Increases statin levels — use lowest effective statin dose, avoid simvastatin/lovastatin
- Tacrolimus/sirolimus: Can cause dyslipidemia; monitor lipids, adjust statin dose
- Colchicine (used in some CNS vasculitis/FMF): Monitor for muscle toxicity when combined with statins